Report: Rite Aid's 2nd bankruptcy is imminent amid reports of more store closures and layoffs
Less than a year after Rite Aid finally wrapped up its first bankruptcy proceedings, it's now reportedly planning to file for Chapter 11 protection a second time.
Most Read from Fast Company
Based on a new report from Bloomberg, Rite Aid employees received a letter today from CEO Matthew Schroeder stating that the company's negotiations with lenders for more capital have failed. He went on to explain that the pharmacy chain can no longer sustain itself and intends to file for Chapter 11 bankruptcy.
Per the letter, the company will start by cutting jobs at its corporate offices in Pennsylvania, a move Schroeder attributed to 'the dramatic downturn in the economy.' An apparent copy of the letter is now making its rounds on Reddit, though Rite Aid has not publicly verified its accuracy.
As of this writing, Rite Aid has not officially confirmed a second bankruptcy filing or publicly acknowledged the alleged impending job cuts. Fast Company has reached out to the pharmacy chain for more information on the report and will update this story accordingly.
Bitter pills
Over the past several years, Rite Aid has struggled with the Sisyphean task of recovering from an initial bankruptcy—but now, it seems that its restructuring efforts have fallen short.
Rite Aid first filed for Chapter 11 back in 2023, a move that was intended to help the company reduce its debt. As part of the process, the chain received a financing commitment of $3.45 billion from lenders.
In the following months, Rite Aid closed hundreds of stores across the U.S. to reduce costs and turn its finances around.
As Fast Company reported in April, Rite Aid store closures have continued this year, with local media in New Jersey, California, and Oregon reporting on such closings recently.
Emerging from bankruptcy a year ago
Last June, Rite Aid asked for court approval of its restructuring plan, which was ultimately granted, allowing the company to emerge from the bankruptcy proceedings in September. At the time, the company reported that it had eliminated $2 billion of total debt and received $2.5 billion in exit financing.
Now, though, it looks like that wasn't enough to get the company back on track. According to several previous reports from Bloomberg, the writing has been on the wall for this second Chapter 11 filing for several weeks.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Latest Rite Aid closings hit Concord, Manchester.
The closings of Rite Aid pharmacy locations across the country have now hit some of the state's largest communities, with multiple closings in Concord, Derry and Manchester. Those cities have at least two stores closing each, according to the latest list of store closings revealed in bankruptcy filings. All of the chain's locations will eventually close, but the exact time is unclear. New Hampshire residents have been posting about Rite Aid closings on social media platforms like Facebook, including one woman who had her prescription moved from the now-closed Pittsfield location to a Concord location, which is now also set to close. Another woman offered 'just a rant' on the closing of the Pittsfield location. 'The Rite Aid closing in Pittsfield wasn't even on my radar even though I knew they were going bankrupt — I just figured there was nooo way they would close a location that serves as the SINGLE pharmacy in a 20 minute radius,' the post reads. The closure list now also includes stores in Hooksett, Hudson, Laconia and Londonderry. The Rite Aid website lists 46 locations in New Hampshire with 26 slated closures so far. Stores in Bristol, Keene and Pittsfield have already permanently closed. The pharmacy chain filed for Chapter 11 bankruptcy in May. It marked the second time it has done so in two years. In Manchester, the two stores closing include a 24-hour location on the West Side by Catholic Medical Center which was relocated in November 2020 as part of redevelopment plans at the hospital. Those plans have since been put on hold. The building is owned by a real estate firm in San Diego, according to city assessor records. A Walgreens is a mile down the road, and a CVS is further down on South Main. Another Rite Aid is across the river on Mammoth Road near Elliot Hospital. The Rite Aid on Mammoth Road is set to close on June 19, with all prescriptions transferred to a CVS pharmacy next door, according to a handwritten sign at the site. A sign at the Hooksett store on Hooksett Road says the location will close on June 26 — with prescriptions also transferred to a nearby CVS. As part of the bankruptcy, CVS agreed to acquire the prescription files of 625 Rite Aid pharmacies across 15 states. CVS purchased Rite Aid locations in Idaho, Oregon and Washington. Bids for Rite Aid's remaining assets, which include unexpired leases for existing Rite Aid stores, are due June 18, according to court documents. Rite Aid Store Closing List Bristol, 360 Summer St. Concord, 165 North State St. Concord, 92 South St. Derry, 20 Crystal Ave. Derry, 52 Rockingham Road Durham, 5 Mill Road Exeter, 75 Portsmouth Ave. Hillsborough, 315 W. Main St. Hooksett, 1285 Hooksett Road Hudson, 71 Lowell Road Jaffrey, 14 Peterborough St. Keene, 354 Winchester St. Laconia, 288 Union Ave. Lee, 58 Calef Highway Lincoln, 50 Main St. Littleton, 136 Meadow St. Londonderry, 123 Nashua Road Manchester, 122 McGregor St. Manchester, 270 Mammoth Road Meredith, 89 NH Route 25 Nashua, 331 Main St. Newport, 51 S. Main St. North Hampton, 72 Lafayette Road Peterborough, 19 Wilton Road Pittsfield, 41 Carroll St. Raymond, 3 Freetown Road Winchester, 10 Main St.
Yahoo
39 minutes ago
- Yahoo
States take legal action as 23andMe attempts to sell customer genetic information amid bankruptcy
Bankrupt 23andMe is facing a lawsuit over its plans to sell customer genetic information. Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S. Bankruptcy Court for the Eastern District of Missouri, the court overseeing the Chapter 11 bankruptcy proceedings that the genetic testing company entered earlier in the year. 23Andme Files For Bankruptcy As California Ag Urges Customers To Delete Data The states contend 23andMe has "no right to sell their customers' genetic identities to the highest bidder" unless the company "first obtain[s] express informed consent to the proposed transaction/transfer by each consumer impacted." They want the bankruptcy court to rule on "whether and to what extent" the genetic testing company can "sell and transfer to a third party such intimate customer data without first obtaining the express informed consent of its customers," according to the filing. In the filing, the states said they were "not objectively opposed to any sale" but "contend that express, informed consent by each customer is necessary before any transfer of that customer's data can take place." Read On The Fox Business App The attorneys general that filed the lawsuit represent Arizona, Colorado, Connecticut, the District of Columbia, Florida, Illinois, Kansas, Kentucky, Louisiana, Maine, Michigan, Minnesota, Missouri, New Hampshire, New Mexico, New York, North Carolina, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Utah, Vermont, Virginia, Washington, West Virginia and Wisconsin. 23Andme Probe Launched To Prevent Customer Dna Data From Being Sold To China Or Other Bad Actors "23andMe cannot auction millions of people's personal genetic information without their consent," New York Attorney General Letitia James said in a statement. "New Yorkers and many others around the country trusted 23andMe with their private information, and they have a right to know what will be done with their information." A spokesperson for 23andMe told FOX Business that the arguments made by the attorneys general in the suit were "without merit." "The sale is permitted under 23andMe privacy policies and applicable law," the spokesperson said. "We required any bidder to adopt our policies and comply with applicable law as a condition to participating in our sales process. Customers will continue to have the same rights and protections in the hands of the winning bidder." The remaining bidders, Regeneron Pharmaceuticals and TTAM Research Institute, "have committed to abide by 23andMe privacy policies, and will continue to operate 23andMe as it has always been operated," according to the 23andMe spokesperson. In May, New York-based Regeneron announced it had been named the successful bidder in the auction for "substantially all" of 23andMe's assets with a $256 million bid. 23Andme Bankruptcy: Will Your Private Data Be Protected? 23andMe subsequently received a $305 million bid from Anne Wojcicki-founded TTAM Research Institute, setting the stage for another auction. The genetic testing company entered Chapter 11 bankruptcy in March to facilitate a sale of its business. In its bankruptcy petition, the company had estimated a range of $100 million to $500 million for its assets, with estimated liabilities in the same range. 23andMe was originally founded in article source: States take legal action as 23andMe attempts to sell customer genetic information amid bankruptcy
Miami Herald
an hour ago
- Miami Herald
Stocks sputter after surprising inflation, China trade news
The stock market needs a new catalyst. Until now, the S&P 500's rally since early April was built on the potential for sellers to be caught off guard by surprising trade deals. Since the benchmark index has rallied 21% after Trump paused reciprocal tariffs on April 9, fewer investors will likely be surprised by developments, and many may be disappointed with outcomes. The possibility that tariff deals may be baked into stock prices appeared when a softer-than-expected May inflation report, alongside what should've been positive China trade news, fell flat. The S&P 500 posted early gains on the news, but reversed to close lower by the end of trading. Related: CPI inflation report resets interest rate cut bets The culprit? While CPI showed inflation was relatively tame last month, most still believe tariffs will cause inflation to reassert itself later this year. Advancing China and the U.S. negotiations are encouraging, but President Trump's comments regarding China tariffs are disheartening. The "meh" reaction to the inflation and China trade news caught the attention of veteran hedge fund manager Doug Kass. Kass has been tracking the markets professionally since the 1970s, and he's the former research director for Leon Cooperman's Omega Advisors, one of the most famous hedge funds in history. After witnessing today's reaction to the news, Kass offered up a frank opinion that may frustrate some investors. Image source: Goodney/Bloomberg via Getty Images The Federal Reserve's mission is to balance inflation and unemployment. It does this by adjusting the Fed Funds Rate. When it increases rates, economic activity slows, crimping inflation but increasing unemployment. When it lowers rates, GDP expands, lowering unemployment but increasing inflation. The dual mandate means that the Fed is in a pickle this year. After the most hawkish monetary policy since the 1980s caused inflation to drop below 3% from over 8% in 2022, the Fed switched gears, cutting rates in September, November, and December to lower unemployment, which has risen to 4.2% from 3.4% in 2023. Related: Billionaire fund manager sends strong message on Fed Chair Powell's future Hopes were for more cuts in 2025, but Fed Chair Powell was forced to pause additional reductions amid sticky inflation and the threat of tariffs driving prices higher. As a result, many Wall Street economists have gone from expecting many cuts this year to none. The CPI report showed that inflation in May only inched up 0.1% month over month, less than the 0.2% predicted. However, headline CPI showed inflation of 2.4% year over year last month, up from 2.3% in April. Meanwhile, core CPI, excluding volatile energy and food prices, was up 2.8% in May, matching April. That's undoubtedly not barn-burning progress. Nevertheless, some latched onto the lower-than-expected increase as evidence that the tariff impact on inflation is overblown, helping stocks in early action. Also contributing to optimism was news out of London that a meeting between Chinese and U.S. officials, including Treasury Secretary Scott Bessent, had led to progress in uncorking supplies of rare earth minerals necessary for EVs and other next-gen technology. President Trump heralded the deal, saying, "OUR DEAL WITH CHINA IS DONE, SUBJECT TO FINAL APPROVAL WITH PRESIDENT XI AND ME. FULL MAGNETS, AND ANY NECESSARY RARE EARTHS, WILL BE SUPPLIED, UP FRONT, BY CHINA. LIKEWISE, WE WILL PROVIDE TO CHINA WHAT WAS AGREED TO, INCLUDING CHINESE STUDENTS USING OUR COLLEGES AND UNIVERSITIES." More Economic Analysis: Hedge-fund manager sees U.S. becoming GreeceA critical industry is slamming the economyReports may show whether the economy is toughing out the tariffs However, details were scant, and Trump threw some cold water onto hopes that a trade deal would ease tariffs on Chinese goods, which already currently stand near 55% all-in. "WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%," he said on Truth Social. Doug Kass has seen more than his share of good and bad tapes. He's survived the 1970s inflation, 1980s skyrocketing interest rates, the S&L crisis, Internet boom and bust, the Great Recession, Covid, and 2022's bear market. Related: Fed official revamps interest-rate cut forecast for rest of this year His experience led to him correctly predicting this year's steep sell-off and his accurate bet that stocks would bounce in early April after the drop. He isn't convinced that the latest inflation progress is bullish for the S&P 500. "The market has likely already discounted a better than expected Core CPI," wrote Kass on TheStreet Pro. "Market participants may interpret this number as being less exciting for equities because companies/manufacturers are likely eating the higher costs/tariffs, leading to concerns about lower margins and profits over the balance of the year." Kass says that "swings in the trade balance" show importers stockpiled inventory ahead of Trump's April 2 "Liberation Day" tariff announcements. As a result, May data still reflects inventory brought in before tariffs hit. "When that inventory runs out, they will likely have to put through price hikes and inflation will heat up," said Kass. Kass is similarly unimpressed by the outcome of the China meeting. "The China/U.S. tariff meeting ended up being a complete non-event (with no evidence of lowering tariffs)," wrote Kass. Absent tariff relief, companies absorbing at least some additional costs will see earnings come under pressure. And since earnings growth is a cornerstone of stock prices and tariffs don't seem destined to retreat further anytime soon, there may be little impetus to support a rip-roaring rally. Related: Veteran fund manager revamps stock market forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
